Advertisement
Research ArticleDrug Discovery and Translational Medicine
Open Access

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705

Article Information

vol. 362 no. 2 338-346
DOI 
https://doi.org/10.1124/jpet.117.240705
PubMed 
28611093
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received February 15, 2017
  • Accepted June 9, 2017
  • Published online July 18, 2017.

Article Versions

Copyright & Usage 
Copyright © 2017 by The Author(s) This is an open access article distributed under the CC BY Attribution 4.0 International license.

Author Information

  1. Jakob Busch-Petersen1,
  2. Donald C. Carpenter,
  3. Miriam Burman2,
  4. James Foley,
  5. Gerald E. Hunsberger,
  6. David J. Kilian,
  7. Michael Salmon3,
  8. Ruth J. Mayer4,
  9. John G. Yonchuk, and
  10. Ruth Tal-Singer
  1. GSK R&D, King of Prussia PA
  1. Address correspondence to:
    Dr. Ruth Tal-Singer, Respiratory Therapy Area Unit, GSK R&D, 709 Swedeland Road, King of Prussia, PA 19406. E-mail: Ruth.M.Tal-Singer{at}gsk.com.
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: June 2017 to September 2023

AbstractFullPdf
Jun 20172070103
Jul 20177723084
Aug 201725294130
Sep 20171215093
Oct 2017157057
Nov 2017165387
Dec 2017144846
Jan 2018185369
Feb 201884962
Mar 20181111999
Apr 2018117455
May 201866259
Jun 201846080
Jul 201836749
Aug 201866331
Sep 201846961
Oct 2018412976
Nov 2018412445
Dec 201836333
Jan 201925526
Feb 201997958
Mar 2019311949
Apr 201998134
May 20191010148
Jun 201947028
Jul 201937643
Aug 201938728
Sep 201947138
Oct 201928539
Nov 201969737
Dec 201949442
Jan 2020118032
Feb 2020117431
Mar 202098321
Apr 202078240
May 202039038
Jun 202016531
Jul 202017621
Aug 202055630
Sep 202069226
Oct 202025917
Nov 202045526
Dec 202096328
Jan 202145529
Feb 202133931
Mar 202184644
Apr 202133024
May 202174841
Jun 202125536
Jul 202144520
Aug 202123819
Sep 202154128
Oct 202132936
Nov 202136344
Dec 202113720
Jan 202265646
Feb 202254620
Mar 202224322
Apr 202254824
May 202223923
Jun 202214219
Jul 20224256
Aug 202223518
Sep 202244430
Oct 202285836
Nov 202203014
Dec 202252916
Jan 202353813
Feb 202372321
Mar 202345426
Apr 202323722
May 2023152221
Jun 2023231717
Jul 202342527
Aug 202343817
Sep 202334028

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

Danirixin: A Reversible and Selective Antagonist of CXCR2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement